Vinorelbine
Based on 23 publication(s) in Google Scholar
Vinorelbine is an anti-mitotic agent which inhibits the proliferation of Hela cells with IC50 of 1.25 nM.
For research use only. We do not sell to patients.
- CAS No.: 71486-22-1
- Formula: C45H54N4O8
- Molecular Weight:778.93
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Vinorelbine
More- Cell Mol Immunol. 2023 Jan;20(1):51-64. [Abstract]
- Cell Rep Med. 2025 Apr 2:102053. [Abstract]
- Sci Adv. 2023 Jun 2;9(22):eadc9273. [Abstract]
- Cell Death Dis. 2026 Apr 3;17(1):449. [Abstract]
- EBioMedicine. 2021 Aug:70:103510. [Abstract]
- Microsyst Nanoeng. 2021 May 24:7:38. [Abstract]
- Acta Pharmacol Sin. 2024 Oct;45(10):2174-2185. [Abstract]
- Biochem Pharmacol. 2020 May;175:113865. [Abstract]
- Microb Cell Fact. 2025 Jan 30;24(1):34. [Abstract]
- Int J Cancer. 2024 Jul 15;155(2):324-338. [Abstract]
- Cancers (Basel). 2021 Jul 2;13(13):3323. [Abstract]
- J Cell Mol Med. 2026 Apr;30(7):e71101. [Abstract]
- Adv Ther. 2024 Jul 18.
- iScience. 2022 Sep 6;25(10):105081. [Abstract]
- J Bone Oncol. 2021 Sep 20:30:100391. [Abstract]
- Transl Lung Cancer Res. 2024 Oct 31;13(10):2698-2712. [Abstract]
- Am J Cancer Res. 2021 Apr 15;11(4):1428-1445. [Abstract]
- Biochem Biophys Res Commun. 2020 May 21;526(1):154-157. [Abstract]
- Int J Clin Pract. 2026 Apr 25;2026(1):6800480.
- Res Sq. 2026 Jan 9.
- bioRxiv. 2026 Jan 9.
- bioRxiv. 2025 Aug 27:2025.08.22.671824. [Abstract]
- Res Sq. 2025 May 16:rs.3.rs-6590535. [Abstract]
-
Histological Imaging/Staining
-
RT-PCR
-
Cell Proliferation/Viability Assay
-
In Vivo Efficacy Study
-
Bio/Physico-chemical Assay
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A2058 | GI50 |
0.002 μM
Compound: Vinorelbine
|
Antiproliferative activity against human A2058 cells assessed as growth inhibition measured for 48 hrs by MTT assay
Antiproliferative activity against human A2058 cells assessed as growth inhibition measured for 48 hrs by MTT assay
|
[PMID: 38833507] |
| A-375 | IC50 |
0.6 nM
Compound: VN
|
Antiproliferative activity against human A-375 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
Antiproliferative activity against human A-375 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
|
[PMID: 38959729] |
| A-431 | IC50 |
60 nM
Compound: Vinorelbine
|
Antiproliferative activity against human A431 cells after 72 hrs by sulforhodamine B assay
Antiproliferative activity against human A431 cells after 72 hrs by sulforhodamine B assay
|
[PMID: 21480626] |
| A549 | IC50 |
0.049 μM
Compound: 1e, AVLB
|
Cytotoxicity against human A549 cells after 72 hrs by SRB assay
Cytotoxicity against human A549 cells after 72 hrs by SRB assay
|
[PMID: 17544278] |
| A549 | IC50 |
36.9 nM
Compound: 1a
|
Cytotoxicity against human A549 cells after 72 hrs by SRB assay
Cytotoxicity against human A549 cells after 72 hrs by SRB assay
|
[PMID: 18771244] |
| A549 | IC50 |
0.03 μM
Compound: 1e
|
Cytotoxicity against human A549 cells by sulforhodamine B assay
Cytotoxicity against human A549 cells by sulforhodamine B assay
|
[PMID: 19499938] |
| A549 | IC50 |
26.1 μM
Compound: vinorelbine
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 20462230] |
| A549 | IC50 |
26.1 μmol
Compound: vinorelbine
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 20462230] |
| A549 | IC50 |
64.6 nM
Compound: Vinorelbine
|
Antiproliferative activity against human A549 cells after 72 hrs by sulforhodamine B assay
Antiproliferative activity against human A549 cells after 72 hrs by sulforhodamine B assay
|
[PMID: 21480626] |
| A549 | IC50 |
10 nM
Compound: 1d
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 22525316] |
| A549 | IC50 |
9 nM
Compound: 1d, NVB
|
Cytotoxicity against human A549 cells after 24 to 72 hrs by MTT assay
Cytotoxicity against human A549 cells after 24 to 72 hrs by MTT assay
|
[PMID: 23107481] |
| A549 | IC50 |
0.6 μM
Compound: Vinorelbine
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
|
[PMID: 33588178] |
| BT-474 | IC50 |
0.3 nM
Compound: VN
|
Antiproliferative activity against human BT-474 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
Antiproliferative activity against human BT-474 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
|
[PMID: 38959729] |
| CAKI-1 | IC50 |
0.3 nM
Compound: VN
|
Antiproliferative activity against human CAKI-1 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
Antiproliferative activity against human CAKI-1 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
|
[PMID: 38959729] |
| HCC1937 | IC50 |
>10 μM
Compound: Vinorelbine
|
Antiproliferative activity against exponentially growing adherent human HCC1937 cells assessed as inhibition of cell proliferation after 72 hrs by luminescence detection based ATPlite assay
Antiproliferative activity against exponentially growing adherent human HCC1937 cells assessed as inhibition of cell proliferation after 72 hrs by luminescence detection based ATPlite assay
|
[PMID: 25872984] |
| HCC44 | GI50 |
0.005 μM
Compound: Vinorelbine
|
Antiproliferative activity against human HCC44 cells assessed as growth inhibition measured for 48 hrs by MTT assay
Antiproliferative activity against human HCC44 cells assessed as growth inhibition measured for 48 hrs by MTT assay
|
[PMID: 38833507] |
| HCT-116 | IC50 |
75 nM
Compound: 22
|
Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by phosphatase assay
Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by phosphatase assay
|
[PMID: 23252481] |
| HCT-116 | IC50 |
35 nM
Compound: 7, VLN
|
Cytotoxicity against human HCT116 cells after 72 hrs by resazurin assay
Cytotoxicity against human HCT116 cells after 72 hrs by resazurin assay
|
[PMID: 23822556] |
| HCT-116 | IC50 |
35 nM
Compound: 4, VLN
|
Antiproliferative activity against human HCT116 cells after 72 hrs
Antiproliferative activity against human HCT116 cells after 72 hrs
|
[PMID: 24871162] |
| HCT-116 | IC50 |
0.015 μM
Compound: Vinorelbine
|
Cytotoxicity against human HCT116 cells after 72 hrs by resazurin-based fluorimetric assay
Cytotoxicity against human HCT116 cells after 72 hrs by resazurin-based fluorimetric assay
|
[PMID: 24901800] |
| HCT-116 | IC50 |
15 nM
Compound: 3, VLN
|
Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 72 hrs
Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 72 hrs
|
[PMID: 25804719] |
| HCT-116 | IC50 |
0.0149 μM
Compound: Vinorelbine
|
Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 32473523] |
| HCT-116/VM46 | IC50 |
600 nM
Compound: 22
|
Cytotoxicity against human vinblastine-resistant HCT116/VM46 cells assessed as growth inhibition after 72 hrs by phosphatase assay
Cytotoxicity against human vinblastine-resistant HCT116/VM46 cells assessed as growth inhibition after 72 hrs by phosphatase assay
|
[PMID: 23252481] |
| HEK293 | GI50 |
0.05 μM
Compound: Vinorelbine
|
Antiproliferative activity against human HEK293 cells assessed as growth inhibition measured for 48 hrs by MTT assay
Antiproliferative activity against human HEK293 cells assessed as growth inhibition measured for 48 hrs by MTT assay
|
[PMID: 38833507] |
| HEK293 | IC50 |
15.9 nM
Compound: VN
|
Antiproliferative activity against human HEK293 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
Antiproliferative activity against human HEK293 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
|
[PMID: 38959729] |
| HeLa | IC50 |
0.026 μM
Compound: 1e, AVLB
|
Cytotoxicity against human HeLa cells after 72 hrs by SRB assay
Cytotoxicity against human HeLa cells after 72 hrs by SRB assay
|
[PMID: 17544278] |
| HeLa | IC50 |
26.9 nM
Compound: 1a
|
Cytotoxicity against human HeLa cells after 72 hrs by SRB assay
Cytotoxicity against human HeLa cells after 72 hrs by SRB assay
|
[PMID: 18771244] |
| HeLa | GI50 |
2.7 nM
Compound: 3
|
Cytotoxicity against human HeLa cells
Cytotoxicity against human HeLa cells
|
[PMID: 19147348] |
| HeLa | IC50 |
0.027 μM
Compound: 1e
|
Cytotoxicity against human HeLa cells by sulforhodamine B assay
Cytotoxicity against human HeLa cells by sulforhodamine B assay
|
[PMID: 19499938] |
| HeLa | IC50 |
27 nM
Compound: 1f, AVBL
|
Cytotoxicity against human HeLa cells by MTT assay
Cytotoxicity against human HeLa cells by MTT assay
|
[PMID: 22115594] |
| HeLa | IC50 |
9 nM
Compound: 1d
|
Cytotoxicity against human HeLa cells by MTT assay
Cytotoxicity against human HeLa cells by MTT assay
|
[PMID: 22525316] |
| HeLa | IC50 |
0.066 μM
Compound: Vinorelbine
|
Inhibition of Ebolavirus glycoprotein/matrix protein VP40 entry in human HeLa cells after 4.5 hrs beta-lactamase reporter assay
Inhibition of Ebolavirus glycoprotein/matrix protein VP40 entry in human HeLa cells after 4.5 hrs beta-lactamase reporter assay
|
[PMID: 29624387] |
| HeLa | IC50 |
0.3 nM
Compound: VN
|
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
|
[PMID: 38959729] |
| HepG2 | IC50 |
23.12 μM
Compound: Vinorelbine
|
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
|
[PMID: 26420067] |
| HepG2 | IC50 |
0.11 μM
Compound: Vinorelbine
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 32473523] |
| HL-60 | IC50 |
<0.06 μM
Compound: vinorelbine
|
Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
|
[PMID: 20462230] |
| HL-60 | IC50 |
<0.06 μmol
Compound: vinorelbine
|
Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
|
[PMID: 20462230] |
| HL-60 | IC50 |
11.47 μM
Compound: Vinorelbine
|
Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
|
[PMID: 26420067] |
| HT-1080 | IC50 |
0.1 nM
Compound: VN
|
Antiproliferative activity against human HT-1080 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
Antiproliferative activity against human HT-1080 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
|
[PMID: 38959729] |
| HT-29 | IC50 |
11.9 nM
Compound: Vinorelbine
|
Antiproliferative activity against human HT-29 cells after 72 hrs by sulforhodamine B assay
Antiproliferative activity against human HT-29 cells after 72 hrs by sulforhodamine B assay
|
[PMID: 21480626] |
| HUVEC | IC50 |
2 nM
Compound: 7, VLN
|
Cytotoxicity against HUVEC after 72 hrs by resazurin assay
Cytotoxicity against HUVEC after 72 hrs by resazurin assay
|
[PMID: 23822556] |
| K562 | IC50 |
20 nM
Compound: 7, VLN
|
Cytotoxicity against human K562 cells after 72 hrs by resazurin assay
Cytotoxicity against human K562 cells after 72 hrs by resazurin assay
|
[PMID: 23822556] |
| K562 | IC50 |
3.5 nM
Compound: 4, VLN
|
Antiproliferative activity against human K562 cells after 72 hrs
Antiproliferative activity against human K562 cells after 72 hrs
|
[PMID: 24871162] |
| K562 | IC50 |
0.006 μM
Compound: Vinorelbine
|
Cytotoxicity against human K562 cells after 72 hrs by resazurin-based fluorimetric assay
Cytotoxicity against human K562 cells after 72 hrs by resazurin-based fluorimetric assay
|
[PMID: 24901800] |
| K562 | IC50 |
6 nM
Compound: 3, VLN
|
Cytotoxicity against human K562 cells assessed as inhibition of cell proliferation after 72 hrs
Cytotoxicity against human K562 cells assessed as inhibition of cell proliferation after 72 hrs
|
[PMID: 25804719] |
| K562 | IC50 |
0.003 μM
Compound: 3; VLN
|
Cytotoxicity against human K562 cells incubated for 72 hrs by CellTiter 96 aqueous one solution reagent based assay
Cytotoxicity against human K562 cells incubated for 72 hrs by CellTiter 96 aqueous one solution reagent based assay
|
[PMID: 27753480] |
| K562 | IC50 |
0.003 μmol
Compound: 3; VLN
|
Cytotoxicity against human K562 cells incubated for 72 hrs by CellTiter 96 aqueous one solution reagent based assay
Cytotoxicity against human K562 cells incubated for 72 hrs by CellTiter 96 aqueous one solution reagent based assay
|
[PMID: 27753480] |
| K-562R | IC50 |
0.41 μM
Compound: 3; VLN
|
Cytotoxicity against doxorubicin-resistant human K562R cells incubated for 72 hrs by CellTiter 96 aqueous one solution reagent based assay
Cytotoxicity against doxorubicin-resistant human K562R cells incubated for 72 hrs by CellTiter 96 aqueous one solution reagent based assay
|
[PMID: 27753480] |
| K-562R | IC50 |
0.41 μmol
Compound: 3; VLN
|
Cytotoxicity against doxorubicin-resistant human K562R cells incubated for 72 hrs by CellTiter 96 aqueous one solution reagent based assay
Cytotoxicity against doxorubicin-resistant human K562R cells incubated for 72 hrs by CellTiter 96 aqueous one solution reagent based assay
|
[PMID: 27753480] |
| KB | EC50 |
6 nM
Compound: Vinorelbine
|
Cell cycle arrest in human KB cells assessed as accumulation of cells at G2/M phase after 24 hrs by propidium iodide-based FACScan
Cell cycle arrest in human KB cells assessed as accumulation of cells at G2/M phase after 24 hrs by propidium iodide-based FACScan
|
[PMID: 21480626] |
| L1210 | IC50 |
65 nM
Compound: 22
|
Cytotoxicity against mouse L1210 cells assessed as growth inhibition after 72 hrs by phosphatase assay
Cytotoxicity against mouse L1210 cells assessed as growth inhibition after 72 hrs by phosphatase assay
|
[PMID: 23252481] |
| MCF7 | GI50 |
2.4 nM
Compound: 3
|
Cytotoxicity against human MCF7 cells
Cytotoxicity against human MCF7 cells
|
[PMID: 19147348] |
| MCF7 | IC50 |
0.07 μM
Compound: vinorelbine
|
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
|
[PMID: 19743863] |
| MCF7 | IC50 |
17.2 μM
Compound: vinorelbine
|
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 20462230] |
| MCF7 | IC50 |
17.2 μmol
Compound: vinorelbine
|
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 20462230] |
| MCF7 | IC50 |
4 nM
Compound: 4, VLN
|
Antiproliferative activity against human MCF7 cells after 72 hrs
Antiproliferative activity against human MCF7 cells after 72 hrs
|
[PMID: 24871162] |
| MCF7 | GI50 |
3.9 nM
Compound: Vinorelbine
|
Antiproliferative activity against human MCF7 cells assessed as growth inhibition measured for 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as growth inhibition measured for 48 hrs by MTT assay
|
[PMID: 38833507] |
| MCF7 | IC50 |
0.8 nM
Compound: VN
|
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
|
[PMID: 38959729] |
| MDA-MB-231 | GI50 |
4.5 nM
Compound: Vinorelbine
|
Antiproliferative activity against human MDA-MB-231 cells assessed as growth inhibition measured for 48 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells assessed as growth inhibition measured for 48 hrs by MTT assay
|
[PMID: 38833507] |
| MDA-MB-468 | IC50 |
0.1 nM
Compound: VN
|
Antiproliferative activity against human MDA-MB-468 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
Antiproliferative activity against human MDA-MB-468 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
|
[PMID: 38959729] |
| MES-SA | IC50 |
0.21 μM
Compound: Vinorelbine
|
Cytotoxicity against human MES-SA cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human MES-SA cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
|
[PMID: 33588178] |
| MES-SA | IC50 |
0.4 nM
Compound: VN
|
Antiproliferative activity against human MES-SA cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
Antiproliferative activity against human MES-SA cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
|
[PMID: 38959729] |
| MES-SA/Dx5 | IC50 |
>32 μM
Compound: Vinorelbine
|
Cytotoxicity against human MES-SA/Dx5 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human MES-SA/Dx5 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
|
[PMID: 33588178] |
| MIA PaCa-2 | GI50 |
0.8 nM
Compound: Vinorelbine
|
Antiproliferative activity against human MIA PaCa-2 cells assessed as growth inhibition measured for 48 hrs by MTT assay
Antiproliferative activity against human MIA PaCa-2 cells assessed as growth inhibition measured for 48 hrs by MTT assay
|
[PMID: 38833507] |
| NCI/ADR-RES | IC50 |
5 μM
Compound: VRB
|
Growth inhibition of doxorubicin-resistant human NCI-ADR-RES cells overexpressing P-glycoprotein after 96 hrs
Growth inhibition of doxorubicin-resistant human NCI-ADR-RES cells overexpressing P-glycoprotein after 96 hrs
|
[PMID: 22044164] |
| NCI/ADR-RES | IC50 |
5 μM
Compound: VRB
|
Cytotoxicity against human NCI/ADR-RES cells assessed as growth inhibition by trypan blue exclusion assay
Cytotoxicity against human NCI/ADR-RES cells assessed as growth inhibition by trypan blue exclusion assay
|
[PMID: 23214452] |
| NCI/ADR-RES | IC50 |
5 μM
Compound: VRB
|
Cytotoxicity against human NCI/ADR-RES cells assessed as growth inhibition after 96 hrs by Giemsa staining-based light microscopy
Cytotoxicity against human NCI/ADR-RES cells assessed as growth inhibition after 96 hrs by Giemsa staining-based light microscopy
|
[PMID: 25025991] |
| NCI/ADR-RES | IC50 |
5 μM
Compound: VRB
|
Cytotoxicity against Pgp overexpressing human NCI-ADR-RES cells assessed as growth inhibition after 48 hrs by SRB assay
Cytotoxicity against Pgp overexpressing human NCI-ADR-RES cells assessed as growth inhibition after 48 hrs by SRB assay
|
[PMID: 26132075] |
| NCI/ADR-RES | IC50 |
5 μM
Compound: VRB
|
Growth inhibition of human NCI/ADR-RES cells after 96 hrs by trypan blue exclusion assay
Growth inhibition of human NCI/ADR-RES cells after 96 hrs by trypan blue exclusion assay
|
[PMID: 29730191] |
| NCI/ADR-RES | IC50 |
5 μM
Compound: Vinorelbine
|
Antiproliferative activity against human NCI/ADR-RES cells assessed as inhibition of cell growth measured after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human NCI/ADR-RES cells assessed as inhibition of cell growth measured after 48 hrs by sulforhodamine B assay
|
[PMID: 37902628] |
| NCI/ADR-RES | IC50 |
3721 nM
Compound: VNR
|
Reversal effect on P-gp-mediated multidrug resistance in human NCI/ADR-RES cells assessed as inhibition of cell proliferation incubated for 72 hrs by SRB assay
Reversal effect on P-gp-mediated multidrug resistance in human NCI/ADR-RES cells assessed as inhibition of cell proliferation incubated for 72 hrs by SRB assay
|
[PMID: 38502936] |
| NCI-H1299 | IC50 |
0.23 μM
Compound: Vinorelbine
|
Cytotoxicity against human NCI-H1299 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human NCI-H1299 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
|
[PMID: 33588178] |
| NCI-H1975 | IC50 |
0.008 μM
Compound: Vinorelbine
|
Cytotoxicity against human NCI-H1975 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human NCI-H1975 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 32473523] |
| NCI-H460 | IC50 |
43.7 nM
Compound: Vinorelbine
|
Antiproliferative activity against human NCI-H460 cells after 72 hrs by sulforhodamine B assay
Antiproliferative activity against human NCI-H460 cells after 72 hrs by sulforhodamine B assay
|
[PMID: 21480626] |
| NCI-H661 | IC50 |
0.12 μM
Compound: Vinorelbine
|
Cytotoxicity against human NCI-H661 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human NCI-H661 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
|
[PMID: 33588178] |
| OVCAR-8 | IC50 |
300 nM
Compound: VRB
|
Growth inhibition of human OVCAR8 cells overexpressing P-glycoprotein after 96 hrs
Growth inhibition of human OVCAR8 cells overexpressing P-glycoprotein after 96 hrs
|
[PMID: 22044164] |
| OVCAR-8 | IC50 |
300 nM
Compound: VRB
|
Cytotoxicity against human OVCAR8 cells assessed as growth inhibition by trypan blue exclusion assay
Cytotoxicity against human OVCAR8 cells assessed as growth inhibition by trypan blue exclusion assay
|
[PMID: 23214452] |
| OVCAR-8 | IC50 |
300 nM
Compound: VRB
|
Cytotoxicity against human OVCAR8 cells assessed as growth inhibition after 96 hrs by Giemsa staining-based light microscopy
Cytotoxicity against human OVCAR8 cells assessed as growth inhibition after 96 hrs by Giemsa staining-based light microscopy
|
[PMID: 25025991] |
| OVCAR-8 | IC50 |
300 nM
Compound: VRB
|
Cytotoxicity against human OVCAR8 cells assessed as growth inhibition after 48 hrs by SRB assay
Cytotoxicity against human OVCAR8 cells assessed as growth inhibition after 48 hrs by SRB assay
|
[PMID: 26132075] |
| OVCAR-8 | IC50 |
300 nM
Compound: VRB
|
Growth inhibition of human OVCAR8 cells after 96 hrs by trypan blue exclusion assay
Growth inhibition of human OVCAR8 cells after 96 hrs by trypan blue exclusion assay
|
[PMID: 29730191] |
| PANC-1 | GI50 |
3 nM
Compound: Vinorelbine
|
Antiproliferative activity against human PANC-1 cells assessed as growth inhibition measured for 48 hrs by MTT assay
Antiproliferative activity against human PANC-1 cells assessed as growth inhibition measured for 48 hrs by MTT assay
|
[PMID: 38833507] |
| SK-OV-3 | IC50 |
26.7 nM
Compound: Vinorelbine
|
Antiproliferative activity against human SKOV3 cells after 72 hrs by sulforhodamine B assay
Antiproliferative activity against human SKOV3 cells after 72 hrs by sulforhodamine B assay
|
[PMID: 21480626] |
| SMMC-7721 | IC50 |
4.7 μM
Compound: vinorelbine
|
Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay
Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay
|
[PMID: 20462230] |
| SMMC-7721 | IC50 |
4.7 μmol
Compound: vinorelbine
|
Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay
Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay
|
[PMID: 20462230] |
| SW480 | IC50 |
>40 μM
Compound: vinorelbine
|
Cytotoxicity against human SW480 cells after 48 hrs by MTT assay
Cytotoxicity against human SW480 cells after 48 hrs by MTT assay
|
[PMID: 20462230] |
| SW480 | IC50 |
>40 μmol
Compound: vinorelbine
|
Cytotoxicity against human SW480 cells after 48 hrs by MTT assay
Cytotoxicity against human SW480 cells after 48 hrs by MTT assay
|
[PMID: 20462230] |
| TERT-RPE1 | IC50 |
9.3 nM
Compound: VN
|
Antiproliferative activity against human RPE-1 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
Antiproliferative activity against human RPE-1 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
|
[PMID: 38959729] |
| U-87MG ATCC | IC50 |
2 nM
Compound: 7, VLN
|
Cytotoxicity against human U87MG cells after 72 hrs by resazurin assay
Cytotoxicity against human U87MG cells after 72 hrs by resazurin assay
|
[PMID: 23822556] |
| U-87MG ATCC | IC50 |
2 nM
Compound: 4, VLN
|
Antiproliferative activity against human U87 cells after 72 hrs
Antiproliferative activity against human U87 cells after 72 hrs
|
[PMID: 24871162] |
| U-87MG ATCC | IC50 |
3.5 nM
Compound: 3, VLN
|
Cytotoxicity against human U87 cells assessed as inhibition of cell proliferation after 72 hrs
Cytotoxicity against human U87 cells assessed as inhibition of cell proliferation after 72 hrs
|
[PMID: 25804719] |
| U-937 | GI50 |
0.004 μM
Compound: Vinorelbine
|
Antiproliferative activity against human U-937 cells assessed as growth inhibition measured for 48 hrs by MTT assay
Antiproliferative activity against human U-937 cells assessed as growth inhibition measured for 48 hrs by MTT assay
|
[PMID: 38833507] |
Vinorelbine (0.5-5 nM) inhibits cell proliferation by 50% (IC50) at concentrations of 1.25 nM. At concentration of 8 nM vinorelbine, no cells are in anaphase[1]. Vinorelbine time-dependently induces the p53 and p21WAFI/CIP1 expression in androgen-dependent (AD) and- independent (AI) prostate cancer cell lines. Vinorelbine stimulates reporter genes in a concentration-dependent manner[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 71486-22-1
-
Molecular Weight 778.93
-
Formula C45H54N4O8
-
SMILES
CC[C@@]1(C=CCN2CC3)[C@@]2([H])[C@@]3(C(C=C([C@](C4=C5C(C=CC=C6)=C6N4)(C[C@@](C=C(CC)C7)([H])C[N@]7C5)C(OC)=O)C(OC)=C8)=C8N9C)[C@]9([H])[C@](C(OC)=O)(O)[C@@H]1OC(C)=O
-
Synonyms
KW-2307 base
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (23)
-
Journal Impact Factor
-
Most Recent
-
Cell Mol Immunol
Arsenic trioxide elicits prophylactic and therapeutic immune responses against solid tumors by inducing necroptosis and ferroptosis. [Abstract]2023 Jan;20(1):51-64. PMID: 36447031
Vinorelbine purchased from MedChemExpress. Usage Cited in: Cell Mol Immunol. 2023 Jan;20(1):51-64. [Abstract]
Comparison of drug (Epirubicin hydrochloride, EPI; Daunorubicin hydrochloride, DNR; Vinorelbine ditartrate, VNR; Oxaliplatin, OXA; Vincristine, VCR; Artemisinin, ART; Colchicine, COL) cytotoxicity to TC1 cells at the indicated doses and time points measured with CCK-8 assays. R.U. (Relative unit) was calculated from the average O.D. values in each condition as the indicator of cell viability (n = 3).
-
Cell Rep Med
CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]2025 Apr 2:102053. PMID: 40187357 -
Sci Adv
Gain-of-function mutations in the catalytic domain of DOT1L promote lung cancer malignant phenotypes via the MAPK/ERK signaling pathway. [Abstract]2023 Jun 2;9(22):eadc9273. PMID: 37256945
Vinorelbine purchased from MedChemExpress. Usage Cited in: Sci Adv. 2023 Jun 2;9(22):eadc9273. [Abstract]
CCK-8 assay data showing the sensitivity of NCI-H460-DOT1L-WT/R231Q cells to cisplatin, vinorelbine, and SGC0946. Cells were treated for 72 hours (Cisplatin and Vinorelbine (0.01-100 μM)) or 6 days (SGC0946). IC50 values were calculated using SPSS V 21.0 software.
Vinorelbine purchased from MedChemExpress. Usage Cited in: Sci Adv. 2023 Jun 2;9(22):eadc9273. [Abstract]
CDX-bearing mice (n = 7 mice per group) were treated with vehicle [10% dimethyl sulfoxide (DMSO) + 40% polyethylene glycol 300 (PEG300) + 5% Tween 80 + 45% saline, five times per week], Cisplatin (3 mg/kg, twice per week), Vinorelbine (4 mg/kg, twice per week), or SGC0946 (20 mg/kg, five times per week) through intraperitoneal administration. The graphs show the tumor images and weights, with the tumor inhibition rate (TIR%). (TIR%) = (1 − average tumor weight after drug treatment/average tumor weight of vehicle control) × 100%.
Vinorelbine purchased from MedChemExpress. Usage Cited in: Sci Adv. 2023 Jun 2;9(22):eadc9273. [Abstract]
Synergistic effect of MAPK inhibition with Cisplatin or Vinorelbine on NCI-H460-DOT1L-R231Q cells after 72 hours of treatment.
-
Cell Death Dis
PMEPA1 modulates YAP1 nuclear translocation to disrupt EMT subtypes and promote metastasis in Biliary tract cancer. [Abstract]2026 Apr 3;17(1):449. PMID: 41932868 -
EBioMedicine
Transcriptomics based multi-dimensional characterization and drug screen in esophageal squamous cell carcinoma. [Abstract]2021 Aug:70:103510. PMID: 34365093
Vinorelbine purchased from MedChemExpress. Usage Cited in: EBioMedicine. 2021 Aug:70:103510. [Abstract]
We compared the actual drug response data of the aforementioned S1/S2 specific agents between S1- and S2-like cells and found that S1-like cell lines were more sensitive to TG-101348, while S2-like cell lines (ESCC cancer cell lines) were more sensitive to Vinorelbine (48 h) and ZM-447439.
-
Microsyst Nanoeng
Double emulsion-pretreated microwell culture for the in vitro production of multicellular spheroids and their in situ analysis. [Abstract]2021 May 24:7:38. PMID: 34567752 -
Acta Pharmacol Sin
A novel FAK-degrading PROTAC molecule exhibited both anti-tumor activities and efficient MDR reversal effects. [Abstract]2024 Oct;45(10):2174-2185. PMID: 38844788 -
Biochem Pharmacol
Precision-engineered reporter cell lines reveal ABCG2 regulation in live lung cancer cells. [Abstract]2020 May;175:113865. PMID: 32142727 -
Microb Cell Fact
Lactobacillus gasseri LGV03-derived indole-3-lactic acid ameliorates immune response by activating aryl hydrocarbon receptor. [Abstract]2025 Jan 30;24(1):34. PMID: 39885499
Vinorelbine purchased from MedChemExpress. Usage Cited in: Microb Cell Fact. 2025 Jan 30;24(1):34. [Abstract]
L. gasseri LGV03 inhibits Vinorelbine (200 μg/mL, 96 h)-induced macrophage reduction in zebrafish model Tg (mpeg-EGFP) (right). Number of macrophages in zebrafish after treatment of Vinorelbine and L. gasseri LGV03 (left).
Vinorelbine purchased from MedChemExpress. Usage Cited in: Microb Cell Fact. 2025 Jan 30;24(1):34. [Abstract]
mRNA gene expression of cytokines TNF-α, TNF-β and IFN-α in zebrafish (Vinorelbine, 200 μg/mL, 96 h).
-
Int J Cancer
Establishment of patient-derived organoids for guiding personalized therapies in breast cancer patients. [Abstract]2024 Jul 15;155(2):324-338. PMID: 38533706 -
Cancers (Basel)
miR-92b-3p Regulates Cell Cycle and Apoptosis by Targeting CDKN1C, Thereby Affecting the Sensitivity of Colorectal Cancer Cells to Chemotherapeutic Drugs. [Abstract]2021 Jul 2;13(13):3323. PMID: 34283053 -
J Cell Mol Med
2026 Apr;30(7):e71101. PMID: 41896195 -
-
iScience
Multiomic characterization and drug testing establish circulating tumor cells as an ex vivo tool for personalized medicine. [Abstract]2022 Sep 6;25(10):105081. PMID: 36204272 -
J Bone Oncol
Identification of GPC3 mutation and upregulation in a multidrug resistant osteosarcoma and its spheroids as therapeutic target. [Abstract]2021 Sep 20:30:100391. PMID: 34611509 -
Transl Lung Cancer Res
Construction of a lung cancer 3D culture model based on alginate/gelatin micro-beads for drug evaluation. [Abstract]2024 Oct 31;13(10):2698-2712. PMID: 39507032 -
Am J Cancer Res
Binding of RNA m6A by IGF2BP3 triggers chemoresistance of HCT8 cells via upregulation of ABCB1. [Abstract]2021 Apr 15;11(4):1428-1445. PMID: 33948366 -
Biochem Biophys Res Commun
Eribulin mesylate-induced c-Fos upregulation enhances cell survival in breast cancer cell lines. [Abstract]2020 May 21;526(1):154-157. PMID: 32201082 -
-
-
-
bioRxiv
2025 Aug 27:2025.08.22.671824. PMID: 40909578 -
Res Sq
Novel mixed cancer-cell models designed to capture inter-patient tumor heterogeneity for accurate evaluation of drug combinations. [Abstract]2025 May 16:rs.3.rs-6590535. PMID: 40470249
Protocol
As defined by the study, VRL1 is diluted in 0.9% NaCl to a concentration of 1.5 mg/mL, and given IV over 5 minutes. The intended treatment interval is 7 days for up to 4 treatments. After receiving 4 weekly doses, cats are eligible to continue VRL treatment every 2 weeks at the owner's expense.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (282 KB)
-
SDS (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Ngan VK, et al. Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic Vinca alkaloids vinorelbine and its newer derivative vinflunine. Mol Pharmacol. 2001 Jul;60(1):225-32. [Content Brief]
[2]. Liu XM, et al. Unique induction of p21(WAF1/CIP1)expression by vinorelbine in androgen-independent prostate cancer cells. Br J Cancer. 2003 Oct 20;89(8):1566-73. [Content Brief]
[3]. Poirier VJ, et al. Toxicity, dosage, and efficacy of vinorelbine (Navelbine) in dogs with spontaneous neoplasia. J Vet Intern Med. 2004 Jul-Aug;18(4):536-9. [Content Brief]
[4]. Pierro JA, et al. Phase I clinical trial of vinorelbine in tumor-bearing cats. J Vet Intern Med. 2013 Jul-Aug;27(4):943-8. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)